A 12-week clinical trial of talsaclidine, a muscarinic agonist, in the treatment of mild to moderate Alzheimer's disease

被引：0
|
作者：
Jones, R
Raschig, A
Müller, A
Müller, S
Ingelheim, B
机构：
[1] Res Inst Care Elderly, Bath, Somerset, England
[2] Boehringer Ingelheim Pharma KG, Biberach, Germany
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
462
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [31] Treatment with selective muscarinic MI agonist talsaclidine lowers the cerebrospinal fluid beta-amyloid levels in Alzheimer patients
    Hager, K
    Magdalena, A
    Raschig, A
    Müller-Spahn, E
    Eschweiler, G
    Heuser, I
    Hampel, H
    Müller-Thomsen, T
    Oertel, W
    Wienrich, M
    Signorell, A
    Gonzalez-Agosti, C
    Nitsch, RM
    Hock, C
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2004, 37 : 6 - 7
  • [32] Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Peskind, ER
    Potkin, SG
    Pomara, N
    Ott, BR
    McDonald, S
    Xie, Y
    Gergel, I
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S332 - S332
  • [33] Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Peskind, E. R.
    Potkin, S. G.
    Pomara, N.
    Ott, B. R.
    McDonald, S.
    Xie, Y.
    Gergel, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 187 - 187
  • [34] Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
    Grossberg, G. T.
    Sadowsky, C.
    Olin, J. T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 651 - 660
  • [35] Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: randomized, controlled trial
    Peskind, ER
    Potkin, SG
    Pomara, N
    Ott, BR
    McDonald, S
    Xie, Y
    Gergel, I
    ANNALS OF NEUROLOGY, 2004, 56 : S49 - S49
  • [36] Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Peskind, ER
    Potkin, SG
    Pomara, N
    Ott, BR
    McDonald, S
    Xie, Y
    Gergel, I
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S207 - S207
  • [37] Memantine, monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Pomara, N
    Peskind, ER
    Potkin, SG
    McDonald, S
    Xie, Y
    Gergel, I
    NEUROBIOLOGY OF AGING, 2004, 25 : S19 - S19
  • [38] EVALUATION OF THE COST EFFECTIVENESS OF THE TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE
    Langsch, L. R.
    VALUE IN HEALTH, 2017, 20 (09) : A860 - A860
  • [39] Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial
    Jia, Yujie
    Zhang, Xuezhu
    Yu, Jianchun
    Han, Jingxian
    Yu, Tao
    Shi, Jiangwei
    Zhao, Lan
    Nie, Kun
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [40] Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
    Yujie Jia
    Xuezhu Zhang
    Jianchun Yu
    Jingxian Han
    Tao Yu
    Jiangwei Shi
    Lan Zhao
    Kun Nie
    BMC Complementary and Alternative Medicine, 17
12345